NR1H4 and metabolic dysfunction-associated steatotic liver disease: Levels of the FXR antagonist DCA are increased in individuals with NAFLD, while levels of the agonist CDCA are decreased, FXR is inhibited, and BA signaling is inhibited (Jiao et al., 2018).